Erika Carmel-Tech Ltd (ERKA) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Erika Carmel-Tech Ltd stock ILS 0.38, price ILS 0.39, that is 0.9% below the price, quality 56 out of 100. Rating: fairly valued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 0.2725 ILS – 19.14 ILS · fair‑value band 0.3145 ILS – 0.4930 ILS · the 0.3860 ILS price screens above the 0.3825 ILS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Erika Carmel-Tech in your weekly email
Every Wednesday you see whether Erika Carmel-Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Erika Carmel-Tech Ltd develops, manufactures, markets, distributes, and sells the B-Cure laser products in Israel and internationally.
Show moreShow less
It provides B-Cure Laser Classic, a non-invasive and safe medical device for the treatment of chronic and acute pain for home use; and B-Cure Laser Pro, a clinically proven, non-invasive and safe medical device for treatment of both acute and chronic conditions.
The company treats achilles tendon inflammation, burns, carpal tunnel syndrome, finger joint pain, fibromyalgia, hip pain, post-dental treatment, lower back pain, neck pain, shoulder pain, knee pain, tennis elbow, toe joint pain, temporomandibular joint disorders, upper back pain, and wounds.
The company was formerly known as Erika B-Cure Laser Ltd and changed its name to Erika Carmel-Tech Ltd in October 2025. Erika Carmel-Tech Ltd was incorporated in 2007 and is headquartered in Haifa, Israel.
Stock analysis
Erika Carmel-Tech Ltd (ERKA) currently trades at 0.3860 ILS, while our model-based Fair Value estimate is 0.3825 ILS, so the stock looks roughly fairly valued today (gap 0.9%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 0.4700 ILS per share, and 6 of the 7 models we run sit above the 0.3860 ILS price.
Bear case: the Asset-Based group reads lowest at 0.1100 ILS, and 1 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.3145 ILS (bear) to 0.4930 ILS (bull), the price of 0.3860 ILS sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Erika Carmel-Tech Ltd reported revenue of 37.3M ILS in FY2025 versus 96.9M ILS in FY2021, a compound −21.2%/yr. Reported net income was −5.9M ILS in FY2025.
Key figures
Market cap 17.8M ILS Micro · P/S ratio 0.54 · EPS (TTM) −0.2600 ILS · Net margin −35.6% · Return on equity −132% · Return on assets (EBIT) −5.6% (5-year average) · Operating margin −43.1% · Revenue (TTM) 33.4M ILS.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −1%, ERKA screens cheaper than that median.
Fair Value models
Bear0.3145 ILSFair Value 0.3825 ILSBull0.4930 ILS
Price 0.3860 ILS · Downside -0.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF0.3700 ILS0.4500 ILS0.5800 ILS82
Growth DCF0.3800 ILS0.4500 ILS0.5600 ILS80
Rev-Margin DCF0.3700 ILS0.4900 ILS0.6400 ILS74
All 7 models by family
DCF Models
FCF DCF0.3700 ILS0.4500 ILS0.5800 ILS82
5Y Revenue Exit0.3700 ILS0.4800 ILS0.6500 ILS73
10Y Revenue Exit0.3600 ILS0.4400 ILS0.5200 ILS68
Multiples
EV/Revenue0.3300 ILS0.4500 ILS0.5800 ILS54
Asset-Based
NCAV (Graham)0.0700 ILS0.1100 ILS0.1400 ILS54
Growth DCF
Growth DCF0.3800 ILS0.4500 ILS0.5600 ILS80
Rev-Margin DCF0.3700 ILS0.4900 ILS0.6400 ILS74
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
20.3% (2020) → −11.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −0.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−2.7% · Above median
Profitability
Return on assets−20.1% · Bottom 25%
Net margin (12 months)−35.6% · Bottom 25%
Operating margin (12 months)−43.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−18.8% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Erika Carmel-Tech Ltd (ERKA) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 0.3825 ILS versus a price of 0.3860 ILS, about 1% lower (fairly valued).
What is the fair value of ERKA?
Our model-based fair value for Erika Carmel-Tech Ltd is 0.3825 ILS (as of Nov 4, 2026), built from audited fundamentals. The current price: 0.3860 ILS.
What is the quality score of ERKA?
Erika Carmel-Tech Ltd has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Erika Carmel-Tech Ltd (ERKA)?
Our model-based price target is the fair value of 0.3825 ILS (as of Nov 4, 2026) from 7 valuation models. Cautious scenario 0.3145 ILS, optimistic scenario 0.4930 ILS. It is a calculation from audited fundamentals, not an analyst target.
What is the Erika Carmel-Tech Ltd stock forecast for 2026?
Our models put fair value at 0.3825 ILS, about 1% lower versus a price of 0.3860 ILS (fairly valued). Cautious scenario 0.3145 ILS, optimistic scenario 0.4930 ILS. The calculation is refreshed regularly with new filings.
What is the revenue of Erika Carmel-Tech Ltd (ERKA)?
Erika Carmel-Tech Ltd reported trailing-twelve-month revenue of about 33.4M ILS (latest available figure, as of Nov 4, 2026).
What growth is priced into Erika Carmel-Tech Ltd (ERKA)?
For today's price to be fair in a discounted-cash-flow model, Erika Carmel-Tech Ltd would have to grow free cash flow by +1.8 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -15.3 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of ERKA use?
Our models discount Erika Carmel-Tech Ltd at 11.9 %: a base by market capitalisation (nano), damped by beta 1.12, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Erika Carmel-Tech Ltd that is +1.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Erika Carmel-Tech Ltd (ERKA) delivered so far?
Over the past 5 years revenue at Erika Carmel-Tech Ltd grew -15.3 % a year. The price currently implies free-cash-flow growth of +1.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Erika Carmel-Tech Ltd (ERKA) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Erika Carmel-Tech Ltd (+1.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Erika Carmel-Tech Ltd (ERKA)?
The free-cash-flow yield on the price is 7.54 %: that much free cash flow Erika Carmel-Tech Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Erika Carmel-Tech Ltd (ERKA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Erika Carmel-Tech Ltd it is 0.3825 ILS per share (as of Nov 4, 2026), against a price of 0.3860 ILS. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Erika Carmel-Tech Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, ERKA trades above its calculated fair value: price 0.3860 ILS, fair value 0.3825 ILS, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ERKA?
No. The price is what the market pays today (0.3860 ILS); the fair value is what the company's own numbers justify (0.3825 ILS). For Erika Carmel-Tech Ltd the two are 0.0035 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is Erika Carmel-Tech Ltd worth?
The market values Erika Carmel-Tech Ltd at about 17.8M ILS (market capitalisation, as of Nov 4, 2026). Per share that is 0.3860 ILS; our models calculate a fair value of 0.3825 ILS per share.
What do the bullish and bearish scenarios say about ERKA?
Our models span a range for Erika Carmel-Tech Ltd: cautious scenario 0.3145 ILS, base 0.3825 ILS, optimistic 0.4930 ILS per share (as of Nov 4, 2026, price 0.3860 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Erika Carmel-Tech Ltd (ERKA)?
Balance-sheet figures for Erika Carmel-Tech Ltd (as of Nov 4, 2026): return on equity −131.8%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is ERKA from its 52-week high?
Erika Carmel-Tech Ltd trades at 0.3860 ILS, about 41% below its 52-week high of 0.6575 ILS and at the low of 0.3860 ILS (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 0.3825 ILS is for.
Which stocks are comparable to Erika Carmel-Tech Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Erika Carmel-Tech Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price 0.3860 ILS, calculated fair value 0.3825 ILS (−1%), Quality Score 56/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ERKA calculated?
We run Erika Carmel-Tech Ltd through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 0.3825 ILS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Erika Carmel-Tech Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Erika Carmel-Tech Ltd (ERKA)?
The closing price on Nov 9, 2026 was 0.3860 ILS. Our model-based fair value is 0.3825 ILS, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Erika Carmel-Tech Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Erika Carmel-Tech Ltd
How large is the market capitalisation of Erika Carmel-Tech Ltd (ERKA)?
The market capitalisation of Erika Carmel-Tech Ltd is 17.8M ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Erika Carmel-Tech Ltd (ERKA)?
The price-to-sales ratio of Erika Carmel-Tech Ltd is 0.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Erika Carmel-Tech Ltd (ERKA)?
Earnings per share at Erika Carmel-Tech Ltd are −0.2600 ILS. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Erika Carmel-Tech Ltd (ERKA)?
The net margin of Erika Carmel-Tech Ltd is −35.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Erika Carmel-Tech Ltd (ERKA)?
The return on equity (ROE) of Erika Carmel-Tech Ltd is −132% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Erika Carmel-Tech Ltd (ERKA)?
On an EBIT basis the return on assets of Erika Carmel-Tech Ltd is −5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Erika Carmel-Tech Ltd (ERKA)?
The operating margin of Erika Carmel-Tech Ltd is −43.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Erika Carmel-Tech Ltd (ERKA)?
Revenue at Erika Carmel-Tech Ltd is growing −18.8% versus a year earlier (3y avg −9.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Erika Carmel-Tech Ltd (ERKA) hold?
Erika Carmel-Tech Ltd holds more cash than debt, 1.3M ILS net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Erika Carmel-Tech Ltd in the live analysis
One click puts Erika Carmel-Tech Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026